Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger Syndrome-A randomized, placebo-controlled, double-blind crossover study

Congenital Heart Disease

Volumn 6, Issue 5, 2011, Pages 424-431

  Mukhopadhyay, Saibal ^a   Nathani, Srikanth ^a   Yusuf, Jamal ^a   Shrimal, Devendra ^a   Tyagi, Sanjay ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Eisenmenger syndrome; Pulmonary vascular resistance; Tadalafil

Indexed keywords

PLACEBO; TADALAFIL;

6 MINUTE WALK TEST DISTANCE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EFFECTIVE PULMONARY BLOOD FLOW; EISENMENGER COMPLEX; EXERCISE; FEMALE; HEADACHE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HUMAN; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; MALE; NOSE CONGESTION; OXYGEN SATURATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC OXYGEN SATURATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; CARBOLINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EISENMENGER COMPLEX; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; INDIA; MALE; OXYGEN; PHOSPHODIESTERASE 5 INHIBITORS; PLACEBO EFFECT; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 80052845151     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2011.00561.x     Document Type: Article

References (34)

1. Wood P. The Eisenmenger Syndrome or pulmonary hypertension with reverse central shunt. Br Med J. 1958;2:701-709.
2. Pietra GG, Capron F, Stewart S, etal. Pathological assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43(suppl 5):25S-32S.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
4. Fernandes SM, Newburger JW, Lang P, etal. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003;91:632-635.
5. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart. 2005;91:1447-1452.
6. Schulz-Neick I, Gilbert N, Ewert R, etal. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicentre study of bosentan. Am Heart J. 2005;150:716, e7-e12.
7. Galiè N, Beghetti M, Gatzoulis MA, etal. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48-54.
8. Chau MC, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger Syndrome vs. idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007;120:301-305.
9. Mukhopadhyay S, Sharma M, Ramakrishnan S, etal. Phosphodiesterase-5 inhibitor in Eisenmenger Syndrome: a preliminary observational study. Circulation. 2006;114:1807-1810.
10. LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res. 1970;4:23-30.
11. Guyatt GH, Sullivan MJ, Thompson PJ, etal. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. CMAJ. 1985;132:919-923.
12. Enright PL, Sherril DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158:1384-1387.
13. Galiè N, Brundage BH, Ghofrani HA, etal. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-2903.
14. Channick RN, Simonneau G, Sitbon O, etal. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.
15. Rubin LJ, Badesch DB, Barst RJ, etal. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
16. Gatzoulis MA, Beghetti M, Galie N, etal. Longer-term bosentan therapy improves functional capacity in Eisenmenger Syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127:27-32.
17. McLaughlin VV. Classification and epidemiology of pulmonary hypertension. Cardiol Clin. 2004;22:327-341.
18. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
19. Humbert M, Morrell NW, Archer SL, etal. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(suppl 1):13S-24S.
20. Rosenthal E, Michelakis ED, Tymchak W, etal. Sildenafil use in patients with the Eisenmenger Syndrome. Circulation. 2004;109:e197.
21. Beghetti M, Galie N. Eisenmenger Syndrome: a clinical perspective in new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53:733-740.
22. Iversen K, Jensen AS, Jensen TV, etal. Combination therapy with bosentan and sildenafil in Eisenmenger Syndrome: a randomized, placebo-controlled, double blinded trial. Eur Heart J. 2010;31:1124-1131.
23. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115:1039-1050.
24. Diller GP, Dimopoulos K, Okonko D, etal. Exercise intolerance in adult congenial heart disease. Comparative severity correlates and prognostic implication. Circulation. 2005;112:828-835.
25. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, etal. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
26. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
27. Rabe KF, Tenor H, Dent G, etal. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:L536-L543.
28. Cohen AH, Hanson K, Morris K, etal. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 1996;97:172-179.
29. Jernigan NL, Resta TC. Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation. Am J Physiol Lung Cell Mol Physiol. 2002;282:L1366-L1375.
30. Ghofrani HA, Voswinckel R, Reichenberger F, etal. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44:1488-1496.
31. Palmieri EA, Affuso F, Fazio S, Lembo D. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med. 2004;141:743-744.
32. Tantini B, Manes A, Fiumana E, etal. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100:131-138.
33. Post MC, Janssens S, Vandewelf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor of mid term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004;25:1651-1656.
34. Dimopoulos K, Inuzuka R, Goletto S, etal. Improved survival among patients with Eisenmenger Syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010;121:20-25.